Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Pfizer (PFE) reported positive topline results from a Phase 3 study of its drug Braftovi, also known as encorafenib, in the treatment of a certain type of colorectal cancer.

The phase 3 program missed both primary and key secondary endpoints, with no statistically significant effects on relevant measures observed for patients receiving investigational treatment ...

On Reddit, fans have settled on Marvel Phase 3 as the MCU's Golden Age. That's Captain America: Civil War, Doctor Strange, Guardians of the Galaxy 2, Spider-Man: Homecoming, Thor: Ragnarok ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Officially approved as of Jan. 15, CSPC’s Phase 3 expansion will include installation of a third cracker that will add 1.6 million tonnes/year (tpy) of ethylene production capacity to the site ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than ...

Before the Ancient One was brought to live-action for the very first time in Doctor Strange, a slew of actors were considered for the role that would eventually go to Tilda Swinton. Among that ...

PUTRAJAYA: Phase Three of the e-invoicing initiative has received over 4,900 early voluntary participants, according to the Inland Revenue Board (LHDN). In a statement Saturday (Jan 18), LHDN ...

Amgen still needs to show that the reduction in Lp(a) is accompanied by lower rates of cardiovascular outcomes, and will endeavour to show that in its phase 3 programme which will start to enrol a ...

“Following the release of our remarkable Phase 2 data, which demonstrated that two 16-mg doses of CYB003 administered three weeks apart provided remission from depression symptoms for 12 months ...

PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.